Alvotech Revenue Drops 31% as Manufacturing Disruptions Hit H1 2026
Event summary
- H1 2026 revenue fell 31% YoY to $211.9M due to manufacturing disruptions
- Adjusted EBITDA dropped 12.7% YoY to $46.9M
- Resubmitted US Biologics License Applications for AVT05, AVT06, and AVT03
- Raised $165M in equity offering and secured $75M term loan
- FDA closed inspection of Reykjavik facility with VAI classification
The big picture
Alvotech's H1 2026 results reflect the growing pains of scaling biosimilar manufacturing, a challenge facing many mid-stage biotech players. The company's strategic focus on regulatory approvals and financial strengthening positions it for potential upside if key catalysts materialize. The biosimilar market remains competitive, with success hinging on both operational execution and timely regulatory decisions.
What we're watching
- Regulatory Catalysts
- Whether FDA approvals for AVT05, AVT06, and AVT03 will materialize in Q4 2026 as anticipated
- Revenue Recovery
- The pace at which manufacturing normalization will translate to top-line growth in H2 2026
- Financial Flexibility
- How Alvotech will deploy its newly raised $240M in capital across pipeline development and working capital needs
Related topics